J&J Completes Tipifarnib Submission For Leukemia Under Pilot 1 Program

The oral oncologic, known by the proposed trade name Zarnestra, could be approved by the end of the first half based on J&J's filing under the continuous marketing application pilot program and an expected six-month review. Submission is premised on Phase II response data.